Harvard Bioscience (HBIO) Assets Average (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Assets Average data on file, last reported at $79.0 million in Q1 2026.

• Assets Average for Q1 2026 came in at $79.0 million, down 23.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $79.0 million (down 23.46% YoY), and the FY2025 annual result was $103.4 million, down 21.7% from the prior year.
• Assets Average steadied at $79.0 million in Q1 2026 per HBIO's latest filing, from $79.0 million in the prior quarter.
• Over five years, Assets Average peaked at $160.2 million in Q1 2022 and troughed at $79.0 million in Q1 2026.
• A 5-year average of $125.3 million and a median of $135.3 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average increased 4.19% in 2022, then sank 39.23% in 2025.
• A 5-year view of Assets Average shows it stood at $146.2 million in 2022, then slipped by 5.22% to $138.6 million in 2023, then fell by 6.94% to $128.9 million in 2024, then tumbled by 38.71% to $79.0 million in 2025, then declined by 0.03% to $79.0 million in 2026.
• Business Quant data shows HBIO's Assets Average at $79.0 million in Q1 2026, $79.0 million in Q4 2025, and $79.0 million in Q3 2025.